Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $355.92M | $7.43 | Not rated | -10.9 | +132.14% |
Ovid Therapeutics Inc. NASDAQ:OVID | $307.29M | $2.33 | Not rated | -7.1 | +82.81% |
MacroGenics, Inc. NASDAQ:MGNX | $235.18M | $3.70 | Not rated | -3.6 | +39.44% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $183.47M | $3.71 | Not rated | -2.6 | +49.28% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $164.93M | $4.03 | Not rated | 1.4 | +58.37% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $134.74M | $2.14 | Not rated | -4.0 | -74.53% |
InflaRx N.V. NASDAQ:IFRX | $125.69M | $1.74 | Not rated | -2.7 | -13.49% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $69.76M | $3.73 | Not rated | -2.5 | -65.57% |
ImageneBio Inc NASDAQ:IMA | $63.05M | $5.59 | Not rated | -1.5 | -37.11% |
Clene Inc. NASDAQ:CLNN | $55.56M | $5.39 | Not rated | -2.1 | -59.54% |
Continue the stock analysis
Jump to another research area for this company.